Myriad Genetics Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Myriad Genetics has an operating margin of -14.7%, meaning the company retains $-15 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -34.2% the prior year.
Myriad Genetics's revenue grew 11.2% year-over-year to $837.6M, a solid pace of expansion. This earns a growth score of 61/100.
Myriad Genetics carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Myriad Genetics's current ratio of 1.82 indicates adequate short-term liquidity, earning a score of 53/100. The company can meet its near-term obligations, though with limited headroom.
Myriad Genetics passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Myriad Genetics generates $0.07 in operating cash flow (-$8.7M OCF vs -$127.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Myriad Genetics earns $-44.1 in operating income for every $1 of interest expense (-$123.5M vs $2.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Myriad Genetics (MYGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Myriad Genetics generated $837.6M in revenue in fiscal year 2024. This represents an increase of 11.2% from the prior year.
Myriad Genetics's EBITDA was -$62.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 68.1% from the prior year.
Myriad Genetics reported -$127.3M in net income in fiscal year 2024. This represents an increase of 51.7% from the prior year.
Myriad Genetics earned $-1.41 per diluted share (EPS) in fiscal year 2024. This represents an increase of 55.7% from the prior year.
Myriad Genetics held $102.4M in cash against $39.6M in long-term debt as of fiscal year 2024.
Myriad Genetics had 91M shares outstanding in fiscal year 2024. This represents an increase of 1.6% from the prior year.
Myriad Genetics's gross margin was 69.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the prior year.
Myriad Genetics's operating margin was -14.7% in fiscal year 2024, reflecting core business profitability. This is up 19.4 percentage points from the prior year.
Myriad Genetics's net profit margin was -15.2% in fiscal year 2024, showing the share of revenue converted to profit. This is up 19.8 percentage points from the prior year.
Myriad Genetics invested $113.4M in research and development in fiscal year 2024. This represents an increase of 27.8% from the prior year.
MYGN Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $205.7M-3.5% | $213.1M+8.8% | $195.9M-7.0% | $210.6M-0.4% | $211.5M+4.6% | $202.2M+2.8% | $196.6M+2.4% | $191.9M |
| Cost of Revenue | $61.9M+1.0% | $61.3M-0.6% | $61.7M+3.4% | $59.7M-7.3% | $64.4M-0.3% | $64.6M+4.9% | $61.6M+6.9% | $57.6M |
| Gross Profit | $143.8M-5.3% | $151.8M+13.1% | $134.2M-11.1% | $150.9M+2.6% | $147.1M+6.9% | $137.6M+1.9% | $135.0M+0.5% | $134.3M |
| R&D Expenses | $28.2M+10.2% | $25.6M-6.9% | $27.5M-16.4% | $32.9M+21.4% | $27.1M+8.8% | $24.9M+18.6% | $21.0M-12.5% | $24.0M |
| SG&A Expenses | $67.9M+1.6% | $66.8M+0.5% | $66.5M+144.7% | -$148.7M-202.6% | $144.9M+3.1% | $140.6M-2.6% | $144.4M+6.1% | $136.1M |
| Operating Income | -$23.3M+92.9% | -$329.2M-1035.2% | -$29.0M+25.8% | -$39.1M-7.1% | -$36.5M-30.8% | -$27.9M+11.1% | -$31.4M+47.8% | -$60.1M |
| Interest Expense | $3.8M+153.3% | $1.5M+87.5% | $800K+14.3% | $700K-12.5% | $800K+60.0% | $500K-44.4% | $900K-10.0% | $1.0M |
| Income Tax | $1.2M+1300.0% | -$100K+99.7% | -$29.3M-987.9% | $3.3M+760.0% | -$500K-600.0% | $100K+109.1% | -$1.1M-1200.0% | $100K |
| Net Income | -$27.4M+91.7% | -$330.5M-330400.0% | -$100K+99.8% | -$42.5M-15.8% | -$36.7M-41.2% | -$26.0M+16.7% | -$31.2M+49.1% | -$61.3M |
| EPS (Diluted) | $-0.29+91.9% | $-3.57 | $0.00+100.0% | $-0.47-14.6% | $-0.41-41.4% | $-0.29+14.7% | $-0.34+54.7% | $-0.75 |
MYGN Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $728.1M+7.5% | $677.3M-32.7% | $1.0B-2.1% | $1.0B-5.3% | $1.1B-2.3% | $1.1B-3.1% | $1.1B-0.2% | $1.1B |
| Current Assets | $344.8M+21.3% | $284.3M-1.0% | $287.2M-3.6% | $298.0M+2.2% | $291.6M+0.4% | $290.3M-7.4% | $313.6M+18.2% | $265.4M |
| Cash & Equivalents | $145.4M+95.4% | $74.4M-19.0% | $91.8M-10.4% | $102.4M+10.8% | $92.4M-4.6% | $96.9M-26.6% | $132.1M+73.8% | $76.0M |
| Inventory | $31.6M+10.1% | $28.7M+1.4% | $28.3M+2.9% | $27.5M+5.4% | $26.1M+6.1% | $24.6M+11.8% | $22.0M-12.4% | $25.1M |
| Accounts Receivable | $118.0M-13.9% | $137.0M+13.8% | $120.4M-0.7% | $121.2M+2.9% | $117.8M-0.3% | $118.1M+3.3% | $114.3M-0.8% | $115.2M |
| Goodwill | $51.6M0.0% | $51.6M-82.0% | $286.3M0.0% | $286.3M0.0% | $286.3M-0.2% | $287.0M-0.1% | $287.4M+0.3% | $286.6M |
| Total Liabilities | $355.3M+22.9% | $289.2M-4.0% | $301.2M-7.7% | $326.5M-5.3% | $344.6M-1.7% | $350.5M-3.5% | $363.3M-22.0% | $465.7M |
| Current Liabilities | $148.0M-26.0% | $199.9M+32.3% | $151.1M-7.9% | $164.1M+10.2% | $148.9M+1.9% | $146.1M-6.3% | $155.9M-25.5% | $209.3M |
| Long-Term Debt | $119.5M | $0-100.0% | $59.3M+49.7% | $39.6M+2.1% | $38.8M+0.3% | $38.7M+0.5% | $38.5M0.0% | $38.5M |
| Total Equity | $372.8M-3.9% | $388.1M-44.9% | $704.9M+0.5% | $701.1M-5.3% | $740.5M-2.6% | $760.0M-3.0% | $783.2M+14.6% | $683.4M |
| Retained Earnings | -$1.1B-2.5% | -$1.1B-43.7% | -$756.9M0.0% | -$756.8M-9.3% | -$692.2M-5.6% | -$655.5M-4.1% | -$629.5M-5.2% | -$598.3M |
MYGN Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $21.1M+255.1% | -$13.6M+16.6% | -$16.3M-347.0% | $6.6M+153.8% | $2.6M+114.0% | -$18.6M+66.0% | -$54.7M-147.5% | -$22.1M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$6.2M+10.1% | -$6.9M+16.9% | -$8.3M-40.7% | -$5.9M+7.8% | -$6.4M+9.9% | -$7.1M+40.8% | -$12.0M-380.0% | -$2.5M |
| Financing Cash Flow | $56.2M+2061.5% | $2.6M-80.9% | $13.6M+547.6% | $2.1M-12.5% | $2.4M+127.3% | -$8.8M-107.2% | $121.9M+4976.0% | -$2.5M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MYGN Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.9%-1.3pp | 71.2%+2.7pp | 68.5%-3.1pp | 71.7%+2.1pp | 69.5%+1.5pp | 68.0%-0.6pp | 68.7%-1.3pp | 70.0% |
| Operating Margin | -11.3%+143.2pp | -154.5%-139.7pp | -14.8%+3.8pp | -18.6%-1.3pp | -17.3%-3.5pp | -13.8%+2.2pp | -16.0%+15.3pp | -31.3% |
| Net Margin | -13.3%+141.8pp | -155.1%-155.0pp | -0.1%+20.1pp | -20.2%-2.8pp | -17.3%-4.5pp | -12.9%+3.0pp | -15.9%+16.1pp | -31.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -3.8%+45.0pp | -48.8%-48.8pp | -0.0%+4.1pp | -4.1%-0.8pp | -3.4%-1.0pp | -2.3%+0.4pp | -2.7%+2.6pp | -5.3% |
| Current Ratio | 2.33+0.9 | 1.42-0.5 | 1.90+0.1 | 1.82-0.1 | 1.96-0.0 | 1.99-0.0 | 2.01+0.7 | 1.27 |
| Debt-to-Equity | 0.32+0.3 | 0.00-0.1 | 0.08+0.0 | 0.060.0 | 0.050.0 | 0.050.0 | 0.050.0 | 0.06 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Myriad Genetics's annual revenue?
Myriad Genetics (MYGN) reported $837.6M in total revenue for fiscal year 2024. This represents a 11.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Myriad Genetics's revenue growing?
Myriad Genetics (MYGN) revenue grew by 11.2% year-over-year, from $753.2M to $837.6M in fiscal year 2024.
Is Myriad Genetics profitable?
No, Myriad Genetics (MYGN) reported a net income of -$127.3M in fiscal year 2024, with a net profit margin of -15.2%.
What is Myriad Genetics's earnings per share (EPS)?
Myriad Genetics (MYGN) reported diluted earnings per share of $-1.41 for fiscal year 2024. This represents a 55.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Myriad Genetics's EBITDA?
Myriad Genetics (MYGN) had EBITDA of -$62.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Myriad Genetics have?
As of fiscal year 2024, Myriad Genetics (MYGN) had $102.4M in cash and equivalents against $39.6M in long-term debt.
What is Myriad Genetics's gross margin?
Myriad Genetics (MYGN) had a gross margin of 69.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Myriad Genetics's operating margin?
Myriad Genetics (MYGN) had an operating margin of -14.7% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Myriad Genetics's net profit margin?
Myriad Genetics (MYGN) had a net profit margin of -15.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Myriad Genetics's operating cash flow?
Myriad Genetics (MYGN) generated -$8.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Myriad Genetics's total assets?
Myriad Genetics (MYGN) had $1.0B in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Myriad Genetics spend on research and development?
Myriad Genetics (MYGN) invested $113.4M in research and development during fiscal year 2024.
How many shares does Myriad Genetics have outstanding?
Myriad Genetics (MYGN) had 91M shares outstanding as of fiscal year 2024.
What is Myriad Genetics's current ratio?
Myriad Genetics (MYGN) had a current ratio of 1.82 as of fiscal year 2024, which is generally considered healthy.
What is Myriad Genetics's debt-to-equity ratio?
Myriad Genetics (MYGN) had a debt-to-equity ratio of 0.06 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Myriad Genetics's return on assets (ROA)?
Myriad Genetics (MYGN) had a return on assets of -12.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Myriad Genetics's cash runway?
Based on fiscal year 2024 data, Myriad Genetics (MYGN) had $102.4M in cash against an annual operating cash burn of $8.7M. This gives an estimated cash runway of approximately 141 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Myriad Genetics's Piotroski F-Score?
Myriad Genetics (MYGN) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Myriad Genetics's earnings high quality?
Myriad Genetics (MYGN) has an earnings quality ratio of 0.07x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Myriad Genetics cover its interest payments?
Myriad Genetics (MYGN) has an interest coverage ratio of -44.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Myriad Genetics?
Myriad Genetics (MYGN) scores 53 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.